Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.32 USD
+0.10 (1.92%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
EDIT 5.32 +0.10(1.92%)
Will EDIT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates
Other News for EDIT
EDIT, CLNE and NIU are among after hour movers
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine management to meet with Oppenheimer
Editas Medicine management to meet with Oppenheimer
Biotech Roundtable: Who will bring the next CRISPR drug to market?